What Is Fibronectin and What Does It Do in the Body?

Fibronectin is a large, sticky glycoprotein that acts as a kind of biological glue, helping cells attach to the scaffolding around them, migrate to where they are needed, and communicate with their neighbors. It exists in two main forms: one that circulates in your blood and another that cells produce locally in tissues. Its fingerprints show up in wound healing, embryonic development, immune defense, and the structural integrity of nearly every organ, which also means that when fibronectin behaves abnormally, the consequences range from chronic scarring diseases to cancer progression.

Two Forms, Two Jobs

Your body makes fibronectin in two distinct versions, and keeping them straight helps explain why this one protein matters in so many different contexts. The plasma form is produced mainly by liver cells and released into the bloodstream, where it circulates at relatively high concentrations. When tissue is injured, plasma fibronectin gets incorporated into the blood clot that forms at the wound site, influencing how platelets behave and helping to stop bleeding.¹ Think of it as an emergency first responder: it is already in the blood, ready to go the moment something goes wrong.

The cellular form, by contrast, is manufactured on-site by cells like fibroblasts. As repair cells migrate into the wound, they produce and assemble their own fibronectin into an insoluble network of fibers in the tissue.¹ This cellular version helps build and remodel the permanent structural matrix that replaces the temporary clot. One gene encodes all fibronectin, but the cell’s splicing machinery can mix and match segments of the gene’s transcript at three different sites, generating a variety of slightly different fibronectin molecules suited to different tissues and situations.²

How Cells Grip Their Surroundings

A cell sitting in tissue needs to hold on to something. Fibronectin provides that handhold. It carries a short amino-acid sequence, abbreviated RGD, that is recognized by a family of cell-surface receptors called integrins.³ When an integrin on a cell’s surface locks onto that RGD tag on fibronectin, the cell gets more than just physical anchorage. The connection triggers internal chemical signals that influence whether the cell grows, moves, differentiates into a specialized type, or even dies. It is a two-way conversation: the cell tugs on fibronectin, and fibronectin’s physical tension feeds information back into the cell.

This mechanical dimension is surprisingly important. Studies using fluorescent probes have shown that fibronectin fibers in living tissue are partially stretched open, with their repeating structural modules unfolded under tension. When that tension is released, the molecules refold.⁴ This stretching is not damage; it is part of how fibronectin works. Pulling the molecule open exposes hidden binding sites for other proteins, essentially turning mechanical force into a biochemical signal. The surrounding matrix matures partly because stretched fibronectin fibers recruit collagens, elastic fibers, and other structural molecules that give each tissue its unique properties.

The Wound-Healing Timeline

If you cut your finger, fibronectin is one of the first molecules on the scene. Plasma fibronectin weaves itself into the fibrin clot within minutes, creating a temporary scaffold called the provisional matrix.⁵ This scaffold does more than just plug the hole. It acts as a landing pad for incoming repair cells, giving them a surface to crawl across and chemical instructions about which direction to move.

As healing progresses, the temporary fibrin-fibronectin matrix is gradually replaced by a more permanent structure rich in collagen and locally produced cellular fibronectin.⁵ Specific binding sites on fibronectin help orchestrate this transition. Research on skin wounds has shown that a particular region on fibronectin, called the synergy site, influences how skin cells migrate across the wound and how strongly fibroblasts remodel the tissue beneath. When that site is experimentally disabled, the skin still closes over the wound, but the scarring response underneath changes: fewer of the contractile cells that drive scar formation appear, and the tissue deposits less fibronectin overall.⁶ That finding hints at a possible lever for reducing excessive scarring, though clinical applications remain far off.

Guiding Embryonic Cells

Before birth, fibronectin serves as a highway system for migrating cells. During embryonic development, cells that will eventually form the heart, nervous system, and other organs travel long distances through fibronectin-rich environments. These matrices do not just provide a surface to move along; they carry directional cues that help cells find their destinations.⁷ In animal experiments, disrupting fibronectin during early development causes lethal defects in the heart and blood vessels, underscoring how fundamental this protein is to building a body from scratch.

When Pathogens Use It Against You

Fibronectin’s talent for sticking to cells has a downside: bacteria have evolved ways to exploit it. Many disease-causing microbes express surface proteins that latch onto fibronectin, essentially using it as a bridge to attach to and invade your cells.⁸ This is not just passive adhesion. For many bacteria, grabbing onto fibronectin is the first step in a chain of events that lets them slip inside host cells, hide from the immune system, and establish chronic infections.

Staphylococcus aureus is one of the best-studied examples. Staph bacteria carry fibronectin-binding proteins on their surface that help them stick to damaged tissue and then invade the cells beneath. This binding capacity contributes directly to biofilm formation, the slimy bacterial communities that are notoriously resistant to antibiotics and immune attack.⁹ The same trick appears in a range of other pathogens, from streptococci to mycobacteria, making fibronectin a recurring vulnerability in infectious disease.

Fibrosis and the Problem of Too Much Repair

Wound healing is supposed to stop once the job is done. When it doesn’t, the result is fibrosis, an excessive buildup of scar-like tissue that stiffens organs and impairs their function. Fibronectin plays a central role in this process, particularly a splice variant called EDA-fibronectin (or ED-A fibronectin) that is normally scarce in healthy adult tissues but reappears during injury and disease.

EDA-fibronectin promotes the conversion of ordinary fibroblasts into myofibroblasts, the hyper-contractile cells that drive scar formation.¹⁰ It does this in part by enhancing the activity of a powerful pro-fibrotic growth signal called TGF-β. Research has shown that the EDA domain increases fibronectin’s ability to capture and activate a latent form of TGF-β, essentially amplifying the scarring signal.¹¹

This mechanism is not theoretical. In studies of idiopathic pulmonary fibrosis, lung fibroblasts from patients with the disease produced substantially more EDA-containing fibronectin than cells from healthy lungs. Mice engineered to lack the EDA domain failed to develop lung fibrosis after an injury that reliably causes it in normal mice, and the protection correlated with reduced TGF-β activation.¹² Similar EDA-driven fibrotic pathways have been implicated in liver and kidney fibrosis, making this splice variant an attractive target for future anti-fibrotic therapies.

Fibronectin’s Complicated Relationship with Cancer

The story of fibronectin in cancer is genuinely messy, and researchers have gone back and forth on it for decades. The protein seems to play opposing roles depending on context. Fibronectin produced by the tumor cells themselves appears to have a suppressive effect on cancer growth. But fibronectin deposited in the surrounding tissue microenvironment promotes tumor progression, helping cancer cells survive, migrate, and resist treatment. Adding to the confusion, higher fibronectin in that same microenvironment has paradoxically been linked to better patient outcomes in some studies.¹³

What makes this contradictory picture partially coherent is the realization that fibronectin is not one thing in cancer. The same splice variants that drive fibrosis, particularly EDA and another called EDB, are also overexpressed in many solid tumors but are nearly absent from normal adult tissues. That tumor-specific expression pattern has made these domains attractive targets for delivering drugs, radioactive tracers, and immune-stimulating molecules directly to cancerous tissue while sparing healthy organs.¹⁴ Several experimental therapies using antibodies or small molecules that home in on EDA or EDB have entered clinical trials, though none has become standard treatment yet.

Fetal Fibronectin and Predicting Preterm Birth

One of the most practical clinical applications of fibronectin has nothing to do with wound healing or cancer. During pregnancy, a specialized form called fetal fibronectin (fFN) normally appears in cervicovaginal secretions early on, disappears in mid-pregnancy, and resurfaces close to delivery. If it shows up too early, it signals that the connection between the fetal membranes and the uterine wall may be loosening ahead of schedule. Levels at or above 50 ng/mL from around 22 weeks onward have been associated with a higher risk of spontaneous preterm birth, and the test is considered one of the strongest available predictors across all populations studied.¹⁵

The test’s real strength, though, lies in its negative predictive value. A negative fFN result is very good at reassuring clinicians that a woman experiencing contractions or other symptoms is unlikely to deliver within the next week or so. Systematic reviews have found that the test is most accurate at predicting preterm birth within seven to ten days of testing in women who show signs of threatened preterm labor but whose cervix has not yet dilated significantly.¹⁶ In practice, combining the fFN result with a measurement of cervical length sharpens the prediction further: women with both a positive fFN test and a short cervix are at substantially higher risk, while women negative on both counts can usually be sent home.¹⁷ That ability to rule out imminent delivery reduces unnecessary hospitalizations, steroid courses, and parental anxiety.

Fibronectin Levels in Critical Illness

Outside obstetrics, plasma fibronectin levels have drawn attention as a marker of how sick someone is. In hospitalized patients with sepsis, liver disease, cancer, major trauma, or burns, circulating fibronectin drops.¹⁸ The decline matters because plasma fibronectin acts as an opsonin, a molecule that tags debris and pathogens for clearance by the body’s scavenger-cell system. When fibronectin is depleted, that clearance system works less efficiently. Research has shown that even a relatively mild insult like elective surgery in an otherwise healthy person can temporarily depress fibronectin levels enough to impair the scavenging machinery.¹⁹

This observation generated enthusiasm in the 1980s for replacing depleted fibronectin through cryoprecipitate transfusions in critically ill patients, but the practice never became widespread. The relationship between low fibronectin and poor outcomes turned out to be more of a signal than a cause: fibronectin drops because the body is consuming it faster than the liver can replace it, and simply topping it off does not necessarily fix the underlying problem. Still, low plasma fibronectin remains a useful red flag in intensive care settings, alerting clinicians that a patient’s scavenging system may be compromised.

Cartilage Breakdown and Joint Disease

Fibronectin has an unexpected dark side in aging joints. When cartilage is damaged by wear or injury, fibronectin in the tissue gets broken into fragments by enzymes. These fragments are not inert debris. A particular fragment, roughly 29 kilodaltons in size, powerfully stimulates cartilage-destroying enzymes and inflammatory responses in the joint cells called chondrocytes.²⁰ The fragment works through an immune-signaling receptor normally involved in detecting bacterial invaders, which means the joint essentially treats its own breakdown products as a threat and mounts an inflammatory response that chews up more cartilage. This creates a vicious cycle: cartilage damage generates fibronectin fragments, which trigger more cartilage damage, which generates more fragments. Understanding this loop has made fibronectin fragments a target of interest for osteoarthritis research, where slowing the cycle could potentially slow joint deterioration.

Tissue Engineering and Scaffold Design

Because fibronectin is so effective at encouraging cells to attach, grow, and specialize, biomedical engineers have been coating synthetic scaffolds with it to improve tissue-engineered grafts. In one study, stem cells seeded onto a fibronectin-coated scaffold showed about 45% greater proliferation compared with cells on uncoated material.²¹ Similar approaches have been tested for bladder reconstruction, where fibronectin-coated silk scaffolds promoted the best attachment of both smooth muscle cells and the lining cells of the urinary tract, and supported the cells’ ability to develop contractile properties after stimulation.²²

The appeal is straightforward: a bare synthetic scaffold is foreign to cells, but coating it with fibronectin gives incoming cells something familiar to grab onto, mimicking the natural tissue environment. The approach has been explored for cartilage repair, bone regeneration, vascular grafts, and organ patches. Challenges remain around keeping the fibronectin coating stable over time and ensuring that the cell behavior it encourages on a small lab scaffold translates to a full-size implant in a patient, but the principle has proven reliable enough that fibronectin coatings are now a standard tool in the tissue-engineering toolkit.

An Ancient Molecule with a Vertebrate Twist

Given how central fibronectin is to so many body processes, you might assume it is a universal feature of animal life. It is not. Fibronectin appears to have evolved relatively recently in biological terms, first appearing in vertebrates. A recognizable fibronectin gene with the same structural layout found in mammals exists in the sea lamprey, one of the most ancient living vertebrates, but nothing comparable has been identified in tunicates or invertebrates.²³ Invertebrates manage cell adhesion and tissue structure with other molecules.

Even among vertebrates, fibronectin has continued to evolve. The RGD integrin-binding motif that is so critical for cell attachment in humans and other jawed vertebrates may not have been present in the earliest fibronectins. Lampreys carry a different, older type of integrin-recognition sequence, suggesting that the RGD-based attachment system evolved after jawed vertebrates split from their jawless relatives.²³ The emergence of fibronectin coincides with the appearance of more complex body plans, closed circulatory systems, and wound-healing demands that simpler organisms do not face, which makes a kind of intuitive sense. You need biological glue when your body is complex enough to have parts that need gluing together.